Please wait while the formulary information is being retrieved.
Drug overview for CALCIUM GLUCONATE-NACL (calcium gluconate in sodium chloride, iso-osmotic):
Generic name: calcium gluconate in sodium chloride, iso-osmotic
Drug class: Calcium
Therapeutic class: Electrolyte Balance-Nutritional Products
Calcium salts are used as a source of calcium, an essential nutrient cation.
Calcium salts are used as a source of calcium cation for the treatment or prevention of calcium depletion in patients in whom dietary measures are inadequate. Conditions that may be associated with calcium deficiency include hypoparathyroidism, achlorhydria, chronic diarrhea, vitamin D deficiency, steatorrhea, sprue, pregnancy and lactation, menopause, pancreatitis, renal failure, alkalosis, and hyperphosphatemia. Administration of certain drugs (e.g., some diuretics, anticonvulsants) may sometimes result in hypocalcemia which may warrant calcium replacement therapy.
Calcium should be administered in long-term electrolyte replacement regimens and is also recommended for the routine prophylaxis of hypocalcemia during transfusions with citrated blood. Administration of calcium salts should not preclude the use of other measures intended to correct the underlying cause of calcium depletion.
Generic name: calcium gluconate in sodium chloride, iso-osmotic
Drug class: Calcium
Therapeutic class: Electrolyte Balance-Nutritional Products
Calcium salts are used as a source of calcium, an essential nutrient cation.
Calcium salts are used as a source of calcium cation for the treatment or prevention of calcium depletion in patients in whom dietary measures are inadequate. Conditions that may be associated with calcium deficiency include hypoparathyroidism, achlorhydria, chronic diarrhea, vitamin D deficiency, steatorrhea, sprue, pregnancy and lactation, menopause, pancreatitis, renal failure, alkalosis, and hyperphosphatemia. Administration of certain drugs (e.g., some diuretics, anticonvulsants) may sometimes result in hypocalcemia which may warrant calcium replacement therapy.
Calcium should be administered in long-term electrolyte replacement regimens and is also recommended for the routine prophylaxis of hypocalcemia during transfusions with citrated blood. Administration of calcium salts should not preclude the use of other measures intended to correct the underlying cause of calcium depletion.
DRUG IMAGES
CALCIUM GLUC 1,000MG/50ML-NACL
CALCIUM GLU 1,000MG/100ML-NACL
CALCIUM GLU 2,000MG/100ML-NACL
The following indications for CALCIUM GLUCONATE-NACL (calcium gluconate in sodium chloride, iso-osmotic) have been approved by the FDA:
Indications:
Cardiac arrest
Hyperkalemia
Hypermagnesemia
Hypocalcemia prevention
Hypocalcemia
Hypocalcemic tetany
Professional Synonyms:
Abnormally decreased serum calcium prophylaxis
Abnormally decreased serum calcium
Elevated serum magnesium
Heart arrest
Hyperpotassemia
Hypocalcemia prophylaxis
Ventricular arrest
Indications:
Cardiac arrest
Hyperkalemia
Hypermagnesemia
Hypocalcemia prevention
Hypocalcemia
Hypocalcemic tetany
Professional Synonyms:
Abnormally decreased serum calcium prophylaxis
Abnormally decreased serum calcium
Elevated serum magnesium
Heart arrest
Hyperpotassemia
Hypocalcemia prophylaxis
Ventricular arrest
The following dosing information is available for CALCIUM GLUCONATE-NACL (calcium gluconate in sodium chloride, iso-osmotic):
Dosage of the oral calcium supplements is usually expressed in grams or mg of elemental calcium and depends on the requirements of the individual patient. Dosage of parenteral calcium replacements is usually expressed as mEq of calcium and depends on individual patient requirements. One mEq of elemental calcium is equivalent to 20 mg.
See Table 1 for the approximate calcium content of the various calcium salts.
Table 1.
Calcium Salt Calcium Content calcium acetate 253 mg (12.7 mEq) per g calcium carbonate 400 mg (20 mEq) per g calcium chloride 270 mg (13.5 mEq) per g calcium citrate 211 mg (10.6 mEq) per g calcium gluceptate 82 mg (4.1 mEq) per g calcium gluconate 90 mg (4.5 mEq) per g calcium glycerophosphate 191 mg (9.6 mEq) per g calcium lactate 130 mg (6.5 mEq) per g calcium phosphate dibasic anhydrous 290 mg (14.5 mEq) per g calcium phosphate dibasic dihydrate 230 mg (11.5 mEq) per g calcium phosphate tribasic 400 mg (20 mEq) per g
Oral calcium supplements usually are administered in 3 or 4 divided doses daily. Optimum calcium absorption may require supplemental vitamin D in individuals with inadequate vitamin D intake, those with impaired renal activation of the vitamin, or those not receiving adequate exposure to sunlight.
If calcium administration is necessary during cardiac arrest, an IV dose of 0.109-0.218 mEq/kg (repeated as necessary) using calcium chloride has been recommended.
Alternatively, adults have been given IV calcium doses of 7-14 mEq using calcium chloride. However, routine administration of calcium in patients with cardiac arrest is not recommended. (See Advanced Cardiovascular Life Support under Uses: Parenteral Preparations.)
If administration of calcium is indicated for the treatment of hypocalcemia, calcium-channel blocker overdosage, hypermagnesemia, or hyperkalemia during pediatric resuscitation, experts recommend a pediatric IV or IO+ calcium dose of 0.272 mEq/kg using calcium chloride. In critically ill children, calcium chloride may provide a greater increase in ionized calcium than calcium gluconate.
The appropriate dose should be administered by slow IV or IO+ injection.
When calcium acetate is used orally to control hyperphosphatemia in adults with chronic renal failure, the recommended initial dosage is 1.334 g of calcium acetate (338 mg of calcium) with each meal. Dosage may be increased gradually according to serum phosphate concentrations, provided hypercalcemia does not occur.
The manufacturer states that most patients require about 2-2.67 g (about 500-680 mg of calcium) with each meal. However, some experts state that the dosage of calcium provided by calcium-containing phosphate binders should not exceed 1.5
g daily and that the total calcium intake (including dietary calcium) should not exceed 2 g daily. These experts state that dialysis patients who remain hyperphosphatemic despite such therapy should receive a calcium-containing phosphate binder in combination with a non-calcium-, non-aluminum-, non-magnesium-containing phosphate binder. The manufacturer recommends that serum calcium concentrations be monitored twice weekly during initiation of calcium acetate therapy and subsequent dosage adjustment; serum phosphorus concentrations also should be monitored periodically.
If hypercalcemia occurs, dosage should be reduced or the salt should be withheld. If severe hypercalcemia occurs, specific measures (e.g., hemodialysis) for the management of overdosage may be necessary. Patients should be advised of the importance of dosage compliance, adherence to instructions about diet, and avoidance of concomitant use of antacids or other preparations containing clinically important concentrations of calcium.
Patients also should be advised of potential manifestations of hypercalcemia.
For the treatment of hyperkalemia with secondary cardiac toxicity, 2.25-14 mEq of calcium may be administered IV while monitoring the ECG. Doses may be repeated after 1-2 minutes if necessary.
Magnesium intoxication in adults is treated initially with 7 mEq of IV calcium; subsequent doses should be adjusted according to patient response. Alternatively, for the treatment of hypermagnesemia in adults, an IV calcium dose of 6.8-13.6
mEq using 10% calcium chloride (5-10 mL) has been administered, and repeated as necessary.
For the treatment of drug-induced cardiovascular emergencies associated with calcium-channel blocking agent toxicity in pediatric patients, an IV calcium dose of 0.272 mEq/kg using 10% calcium chloride (0.2 mL/kg) has been administered over 5-10 minutes; if a beneficial effect was observed, an IV calcium infusion of 0.27-0.68
mEq/kg per hour using calcium chloride has been administered. Ionized calcium concentrations should be monitored to prevent hypercalcemia.
Calcium is also administered IV during exchange transfusions in neonates in a dosage of 0.45 mEq of calcium after every 100 mL of citrated blood exchanged. In adults receiving transfusions of citrated blood, about 1.35
mEq of calcium should be administered IV concurrently with each 100 mL of citrated blood.
In the calcium infusion test+, calcium is given IV in a dosage of 0.25 mEq/kg per hour for a 3-hour period; serum gastrin concentrations are determined 30 minutes before the infusion, at the start of the infusion, and at 30-minute intervals thereafter for 4 hours. In most patients with Zollinger-Ellison syndrome, preinfusion serum gastrin concentrations increase by more than 50% or by greater than 500 pg/mL during the infusion.
In the diagnosis of medullary thyroid carcinoma+, about 7 mEq of calcium is given IV over 5-10 minutes. In patients with medullary thyroid carcinoma, plasma calcitonin concentrations are elevated above normal basal concentrations.
See Table 1 for the approximate calcium content of the various calcium salts.
Table 1.
Calcium Salt Calcium Content calcium acetate 253 mg (12.7 mEq) per g calcium carbonate 400 mg (20 mEq) per g calcium chloride 270 mg (13.5 mEq) per g calcium citrate 211 mg (10.6 mEq) per g calcium gluceptate 82 mg (4.1 mEq) per g calcium gluconate 90 mg (4.5 mEq) per g calcium glycerophosphate 191 mg (9.6 mEq) per g calcium lactate 130 mg (6.5 mEq) per g calcium phosphate dibasic anhydrous 290 mg (14.5 mEq) per g calcium phosphate dibasic dihydrate 230 mg (11.5 mEq) per g calcium phosphate tribasic 400 mg (20 mEq) per g
Oral calcium supplements usually are administered in 3 or 4 divided doses daily. Optimum calcium absorption may require supplemental vitamin D in individuals with inadequate vitamin D intake, those with impaired renal activation of the vitamin, or those not receiving adequate exposure to sunlight.
If calcium administration is necessary during cardiac arrest, an IV dose of 0.109-0.218 mEq/kg (repeated as necessary) using calcium chloride has been recommended.
Alternatively, adults have been given IV calcium doses of 7-14 mEq using calcium chloride. However, routine administration of calcium in patients with cardiac arrest is not recommended. (See Advanced Cardiovascular Life Support under Uses: Parenteral Preparations.)
If administration of calcium is indicated for the treatment of hypocalcemia, calcium-channel blocker overdosage, hypermagnesemia, or hyperkalemia during pediatric resuscitation, experts recommend a pediatric IV or IO+ calcium dose of 0.272 mEq/kg using calcium chloride. In critically ill children, calcium chloride may provide a greater increase in ionized calcium than calcium gluconate.
The appropriate dose should be administered by slow IV or IO+ injection.
When calcium acetate is used orally to control hyperphosphatemia in adults with chronic renal failure, the recommended initial dosage is 1.334 g of calcium acetate (338 mg of calcium) with each meal. Dosage may be increased gradually according to serum phosphate concentrations, provided hypercalcemia does not occur.
The manufacturer states that most patients require about 2-2.67 g (about 500-680 mg of calcium) with each meal. However, some experts state that the dosage of calcium provided by calcium-containing phosphate binders should not exceed 1.5
g daily and that the total calcium intake (including dietary calcium) should not exceed 2 g daily. These experts state that dialysis patients who remain hyperphosphatemic despite such therapy should receive a calcium-containing phosphate binder in combination with a non-calcium-, non-aluminum-, non-magnesium-containing phosphate binder. The manufacturer recommends that serum calcium concentrations be monitored twice weekly during initiation of calcium acetate therapy and subsequent dosage adjustment; serum phosphorus concentrations also should be monitored periodically.
If hypercalcemia occurs, dosage should be reduced or the salt should be withheld. If severe hypercalcemia occurs, specific measures (e.g., hemodialysis) for the management of overdosage may be necessary. Patients should be advised of the importance of dosage compliance, adherence to instructions about diet, and avoidance of concomitant use of antacids or other preparations containing clinically important concentrations of calcium.
Patients also should be advised of potential manifestations of hypercalcemia.
For the treatment of hyperkalemia with secondary cardiac toxicity, 2.25-14 mEq of calcium may be administered IV while monitoring the ECG. Doses may be repeated after 1-2 minutes if necessary.
Magnesium intoxication in adults is treated initially with 7 mEq of IV calcium; subsequent doses should be adjusted according to patient response. Alternatively, for the treatment of hypermagnesemia in adults, an IV calcium dose of 6.8-13.6
mEq using 10% calcium chloride (5-10 mL) has been administered, and repeated as necessary.
For the treatment of drug-induced cardiovascular emergencies associated with calcium-channel blocking agent toxicity in pediatric patients, an IV calcium dose of 0.272 mEq/kg using 10% calcium chloride (0.2 mL/kg) has been administered over 5-10 minutes; if a beneficial effect was observed, an IV calcium infusion of 0.27-0.68
mEq/kg per hour using calcium chloride has been administered. Ionized calcium concentrations should be monitored to prevent hypercalcemia.
Calcium is also administered IV during exchange transfusions in neonates in a dosage of 0.45 mEq of calcium after every 100 mL of citrated blood exchanged. In adults receiving transfusions of citrated blood, about 1.35
mEq of calcium should be administered IV concurrently with each 100 mL of citrated blood.
In the calcium infusion test+, calcium is given IV in a dosage of 0.25 mEq/kg per hour for a 3-hour period; serum gastrin concentrations are determined 30 minutes before the infusion, at the start of the infusion, and at 30-minute intervals thereafter for 4 hours. In most patients with Zollinger-Ellison syndrome, preinfusion serum gastrin concentrations increase by more than 50% or by greater than 500 pg/mL during the infusion.
In the diagnosis of medullary thyroid carcinoma+, about 7 mEq of calcium is given IV over 5-10 minutes. In patients with medullary thyroid carcinoma, plasma calcitonin concentrations are elevated above normal basal concentrations.
The acetate, carbonate, citrate, gluconate, lactate, and phosphate salts of calcium are administered orally. It has been recommended that most oral calcium supplements be administered 1-1.5 hours after meals or with a demulcent (e.g., milk).
However, calcium carbonate powder (i.e., CAL CARB-HD(R)) should generally be administered with meals, since the manufacturer recommends mixing the powder with food for administration. Calcium salts used to bind dietary phosphate in patients with end-stage renal disease should be administered with meals (e.g., 10-15 minutes before, or during, the meal). Calcium chloride and calcium gluconate may be administered IV.
Calcium chloride also may be administered by intraosseous (IO) injection+ in the setting of pediatric resuscitation; onset of action and systemic concentrations are comparable to those achieved with venous administration. Parenteral calcium salts may be administered in large volume IV infusion fluids. IV calcium injections must be administered slowly at a rate not exceeding 0.7-1.8
mEq/minute, and the injection should be stopped if the patient complains of discomfort. Following IV injection, the patient should remain recumbent for a short time. Close monitoring of serum calcium concentrations is essential during IV administration of calcium.
Calcium chloride should not be injected IM or into subcutaneous or perivascular tissue, since severe necrosis and sloughing may occur. Although other calcium salts may cause mild to severe local reactions, they are generally less irritating than calcium chloride. (See Cautions.) The fixed combination of calcium glycerophosphate and calcium lactate is injected IM.
Although some manufacturers previously stated that calcium gluconate could be injected IM when IV administration was not possible, manufacturers of calcium gluconate currently state that the drug should not be injected IM or into subcutaneous tissue because of the potential for severe local reactions. In children, calcium salts should not be administered through scalp veins. Oral administration of calcium supplements or calcium-rich foods should replace parenteral calcium therapy as soon as possible.
The interaction of calcium and phosphate in parenteral nutrition solutions is a complex phenomenon; various factors have been identified as playing a role in the solubility or precipitation of a given combination. Calcium salts are conditionally compatible with phosphate in parenteral nutrition solutions; incompatibility is dependent on a solubility and concentration phenomenon and is not entirely predictable. Precipitation may occur during compounding or at some time after compounding is completed. Specialized references should be consulted for specific compatibility information.
However, calcium carbonate powder (i.e., CAL CARB-HD(R)) should generally be administered with meals, since the manufacturer recommends mixing the powder with food for administration. Calcium salts used to bind dietary phosphate in patients with end-stage renal disease should be administered with meals (e.g., 10-15 minutes before, or during, the meal). Calcium chloride and calcium gluconate may be administered IV.
Calcium chloride also may be administered by intraosseous (IO) injection+ in the setting of pediatric resuscitation; onset of action and systemic concentrations are comparable to those achieved with venous administration. Parenteral calcium salts may be administered in large volume IV infusion fluids. IV calcium injections must be administered slowly at a rate not exceeding 0.7-1.8
mEq/minute, and the injection should be stopped if the patient complains of discomfort. Following IV injection, the patient should remain recumbent for a short time. Close monitoring of serum calcium concentrations is essential during IV administration of calcium.
Calcium chloride should not be injected IM or into subcutaneous or perivascular tissue, since severe necrosis and sloughing may occur. Although other calcium salts may cause mild to severe local reactions, they are generally less irritating than calcium chloride. (See Cautions.) The fixed combination of calcium glycerophosphate and calcium lactate is injected IM.
Although some manufacturers previously stated that calcium gluconate could be injected IM when IV administration was not possible, manufacturers of calcium gluconate currently state that the drug should not be injected IM or into subcutaneous tissue because of the potential for severe local reactions. In children, calcium salts should not be administered through scalp veins. Oral administration of calcium supplements or calcium-rich foods should replace parenteral calcium therapy as soon as possible.
The interaction of calcium and phosphate in parenteral nutrition solutions is a complex phenomenon; various factors have been identified as playing a role in the solubility or precipitation of a given combination. Calcium salts are conditionally compatible with phosphate in parenteral nutrition solutions; incompatibility is dependent on a solubility and concentration phenomenon and is not entirely predictable. Precipitation may occur during compounding or at some time after compounding is completed. Specialized references should be consulted for specific compatibility information.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for CALCIUM GLUCONATE-NACL (calcium gluconate in sodium chloride, iso-osmotic):
There are 0 contraindications.
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Intravenous Ceftriaxone/Intravenous Calcium Products SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Intravenous ceftriaxone and intravenous calcium may form an insoluble precipitate if administered too closely together. CLINICAL EFFECTS: Intravenous administration of calcium-containing products with intravenous ceftriaxone may have serious risks in all patients, especially in the neonate population. NEONATES: Intravenous administration of calcium-containing products within 48(1-2) to 120(3) hours of intravenous administration of ceftriaxone may result in damage to the lungs and/or kidneys in neonates. Fatalities in neonates have been reported.(1-7) OLDER CHILDREN and ADULTS: Sequential administration requires proper line flushing. Use within 48 hours may result in the formation of kidney stones in older children(5) and the formation of "sludge" in the gallbladder.(2) Simultaneous administration in patients older than 28 days may result in the formation of an insoluble ceftriaxone-calcium precipitate.(1-7) PREDISPOSING FACTORS: Neonates, both preterm and term, may be a greatest risk of death from this interaction.(1-4) Young age may predispose patients to formation of ceftriaxone-calcium precipitates in the kidney.(5) High doses of ceftriaxone may also increase the risk of precipitates.(6) PATIENT MANAGEMENT: The US manufacturer of ceftriaxone, Health Canada, and the US Food and Drug Administration (FDA) state that the concomitant use of ceftriaxone and intravenous calcium-containing products is contraindicated in neonates less than or equal to 28 days of age. Ceftriaxone should not be used in neonates less than or equal to 28 days of age if they are receiving or are expected to receive calcium-containing intravenous products.(2,3,7) The US manufacturer of ceftriaxone, Health Canada, and the US FDA state that in patients older than 28 days of age, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid.(2,3,7) The US manufacturer of ceftriaxone, Health Canada, and the US FDA state that ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions via a Y-site in any age group.(2,3,7) DISCUSSION: Isolated reports of neonatal (both term and preterm infants) deaths have been associated with ceftriaxone-calcium precipitates in the lungs and kidneys. A total of 7 cases have been reported to the FDA, resulting in 5 deaths. All 5 deaths were in neonates of 3 weeks or less in age. Six of the 7 patients received calcium gluconate, 1 received calcium via hyperalimentation.(6) In some cases, ceftriaxone and the calcium product were administered by different routes,(1) lines,(2) and/or at different times.(1,2) Reports of a ceftriaxone-calcium salt precipitate in the gall-bladder have also been reported.(2) In in vitro studies in adult and neonatal plasma, ceftriaxone recovery was examined with ceftriaxone concentrations up to 1 mM (in excess of concentrations seen with 2 g ceftriaxone infused over 30 minutes) and calcium concentrations up to 12 mM (48 mg/dL). Ceftriaxone recovery was reduced with calcium concentrations of 6 mM (24 mg/dL) in adult plasma and 4 mM (16 mg/dL) in neonatal plasma. This may indicate ceftriaxone-calcium precipitation formation.(2,7) There have been no reports associated with concurrent use of oral calcium products and the US manufacturer of ceftriaxone states that there is no risk with oral calcium products or use of intramuscular ceftriaxone.(4) |
CEFTRIAXONE, CEFTRIAXONE SODIUM |
| Digitalis Glycosides/Intravenous Calcium Products SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The mechanism of action of digitalis glycosides involves its ability to cause an increase in excitation-contraction coupling mediated through the effects of calcium. Excitable tissues in the heart experience inhibition of sodium/potassium ATPase (the membrane "sodium pump") by digitalis glycosides and so attain relatively higher intracellular sodium and lower potassium concentrations. Higher intracellular sodium concentrations facilitate exchange of extracellular calcium ions and the inward and internal flux of calcium results in modified transmembrane potentials and stronger contractions of cardiac muscle. Elevated extracellular concentrations of calcium after parenteral calcium salts further facilitate these inward calcium fluxes. CLINICAL EFFECTS: Rapid administration of calcium via the intravenous route may result in digitalis toxicity, including arrhythmias.(1) PREDISPOSING FACTORS: Low body weight, advanced age, impaired renal function, hypokalemia, hypercalcemia, and/or hypomagnesemia may increase the risk of digoxin toxicity. PATIENT MANAGEMENT: In patients maintain on a digitalis glycosides, administer intravenous calcium slowly and with caution. If cardiac toxicity develops, supportive measures without additional antiarrhythmics may be sufficient. DISCUSSION: Effects of digitalis glycosides on the heart are increased by elevated extracellular concentrations of ionic calcium. Intravenous administration of calcium salts during digitalis therapy may result in altered cardiac electrophysiologic activity such as tachycardia or arrhythmias. Oral calcium carbonate has not been shown to affect the bioavailability of oral digitalis. |
DIGITEK, DIGOXIN, DIGOXIN MICRONIZED, LANOXIN, LANOXIN PEDIATRIC |
There are 0 moderate interactions.
The following contraindication information is available for CALCIUM GLUCONATE-NACL (calcium gluconate in sodium chloride, iso-osmotic):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 2 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Digitalis toxicity |
| Hypercalcemia |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
| Hypercalcinuria |
There are 3 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Sarcoidosis |
The following adverse reaction information is available for CALCIUM GLUCONATE-NACL (calcium gluconate in sodium chloride, iso-osmotic):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 8 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Hypotension |
None. |
| Rare/Very Rare |
|---|
|
Bradycardia Calcinosis cutis Cardiac arrest Cardiac arrhythmia Extravasation injury Hypercalcemia Tissue necrosis |
There are 14 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Flushing Hyperhidrosis Nausea Paresthesia Vomiting |
Injection site inflammation |
| Rare/Very Rare |
|---|
|
Dysgeusia Fatigue Headache disorder Irritability Polydipsia Syncope Vasodilation of blood vessels Xerostomia |
The following precautions are available for CALCIUM GLUCONATE-NACL (calcium gluconate in sodium chloride, iso-osmotic):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for CALCIUM GLUCONATE-NACL (calcium gluconate in sodium chloride, iso-osmotic):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for CALCIUM GLUCONATE-NACL (calcium gluconate in sodium chloride, iso-osmotic)'s list of indications:
| Cardiac arrest | |
| I46 | Cardiac arrest |
| I46.2 | Cardiac arrest due to underlying cardiac condition |
| I46.8 | Cardiac arrest due to other underlying condition |
| I46.9 | Cardiac arrest, cause unspecified |
| I97.12 | Postprocedural cardiac arrest |
| I97.120 | Postprocedural cardiac arrest following cardiac surgery |
| I97.121 | Postprocedural cardiac arrest following other surgery |
| I97.71 | Intraoperative cardiac arrest |
| I97.710 | Intraoperative cardiac arrest during cardiac surgery |
| I97.711 | Intraoperative cardiac arrest during other surgery |
| O03.36 | Cardiac arrest following incomplete spontaneous abortion |
| O03.86 | Cardiac arrest following complete or unspecified spontaneous abortion |
| O04.86 | Cardiac arrest following (induced) termination of pregnancy |
| O07.36 | Cardiac arrest following failed attempted termination of pregnancy |
| O08.81 | Cardiac arrest following an ectopic and molar pregnancy |
| O29.11 | Cardiac arrest due to anesthesia during pregnancy |
| O29.111 | Cardiac arrest due to anesthesia during pregnancy, first trimester |
| O29.112 | Cardiac arrest due to anesthesia during pregnancy, second trimester |
| O29.113 | Cardiac arrest due to anesthesia during pregnancy, third trimester |
| O29.119 | Cardiac arrest due to anesthesia during pregnancy, unspecified trimester |
| P29.81 | Cardiac arrest of newborn |
| Hyperkalemia | |
| E87.5 | Hyperkalemia |
| Hypermagnesemia | |
| E83.41 | Hypermagnesemia |
| Hypocalcemia | |
| E20.810 | Autosomal dominant hypocalcemia |
| E83.51 | Hypocalcemia |
| P71.0 | Cow's milk hypocalcemia in newborn |
| P71.1 | Other neonatal hypocalcemia |
| Hypocalcemia prevention | |
| E58 | Dietary calcium deficiency |
| Hypocalcemic tetany | |
| E83.51 | Hypocalcemia |
| R29.0 | Tetany |
Formulary Reference Tool